查看“L1196M”的源代码

<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;">

    <div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;">
        <p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;">
            <strong>L1196M</strong> 是 <strong>[[ALK]]</strong>（Anaplastic Lymphoma Kinase）激酶结构域中的一种错义突变，被称为 ALK 基因的<strong>“守门员突变”</strong>（Gatekeeper Mutation）。它约占 ALK 阳性非小细胞肺癌（NSCLC）患者对第一代抑制剂<strong>[[克唑替尼]]</strong>（Crizotinib）获得性耐药机制的 7% ~ 10%。该突变在功能上与 EGFR 基因的 <strong>[[T790M]]</strong> 突变高度相似：通过引入侧链较大的氨基酸（甲硫氨酸），产生<strong>空间位阻</strong>，阻碍克唑替尼结合，但通常对第二代（如阿来替尼、布格替尼）和第三代（洛拉替尼）ALK 抑制剂保持敏感。
        </p>
    </div>

    <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;">
        
        <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;">
            <div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">L1196M</div>
            <div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">ALK Gatekeeper Mutation (点击展开)</div>
        </div>
        
        <div class="mw-collapsible-content">
            <div style="padding: 25px; text-align: center; background-color: #f8fafc;">
                <div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);">
                    [[Image:ALK_L1196M_mutation_structure_steric_hindrance.png|100px|L1196M 空间位阻示意图]]
                </div>
                <div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">阻挡一代药，放行二代药</div>
            </div>

            <table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;">
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">所属基因</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;"><strong>[[ALK]]</strong> (Exon 23)</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">突变类型</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">错义突变 (Missense)</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">氨基酸改变</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">Leu1196 → Met</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">功能分类</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #b91c1c;"><strong>守门员突变</strong> (Gatekeeper)</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">耐药药物</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #b91c1c;">[[克唑替尼]]</td>
                </tr>
                 <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">敏感药物</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #166534;">阿来替尼, 布格替尼<br>洛拉替尼, 恩沙替尼</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">相似突变</th>
                    <td style="padding: 6px 12px; color: #0f172a;">EGFR <strong>[[T790M]]</strong><br>BCR-ABL <strong>[[T315I]]</strong></td>
                </tr>
            </table>
        </div>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：空间位阻 (Steric Hindrance)</h2>
    
    <p style="margin: 15px 0; text-align: justify;">
        L1196 位于 ALK 激酶结构域 ATP 结合口袋的深处，被称为“守门员”位置（Gatekeeper position），控制着抑制剂进入疏水后袋（Hydrophobic back pocket）的通道。
    </p>

    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;"><strong>正常状态 (L1196)：</strong> 野生型的<strong>亮氨酸</strong> (Leucine) 侧链较小，允许克唑替尼等 I 型抑制剂顺利进入结合口袋。</li>
        <li style="margin-bottom: 12px;"><strong>突变状态 (1196M)：</strong> 突变为<strong>甲硫氨酸</strong> (Methionine) 后，侧链体积变大且更长。这种庞大的侧链伸入 ATP 结合口袋，产生了直接的<strong>空间位阻</strong>，在物理上把克唑替尼“挤”了出去，导致药物亲和力下降数百倍。</li>
        <li style="margin-bottom: 12px;"><strong>二代药的对策：</strong> 阿来替尼和布格替尼等药物具有更灵活的分子骨架或不同的结合模式，能够绕过或容忍这个突出的甲硫氨酸侧链，因此仍能保持对 L1196M 的抑制活性。</li>
    </ul>

    <h2 style="background: #fff1f2; color: #9f1239; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #9f1239; font-weight: bold;">临床策略：从一代到三代</h2>
    <div style="background-color: #fff5f5; border-left: 5px solid #e11d48; padding: 15px 20px; margin: 20px 0; border-radius: 4px;">
        <h3 style="margin-top: 0; color: #be123c; font-size: 1.1em;">并非“不可战胜”的耐药</h3>
        <p style="margin-bottom: 0; text-align: justify; font-size: 0.95em; color: #334155;">
            与“溶剂前沿突变” G1202R 导致的广泛耐药不同，L1196M 属于相对“温和”的耐药突变，大多数二代 ALK-TKI 都能有效控制。
        </p>
    </div>

    <div style="overflow-x: auto; margin: 30px auto; max-width: 95%;">
        <table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.95em; text-align: left;">
            <tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;">
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">药物代次</th>
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af; width: 30%;">针对 L1196M 的活性</th>
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569; width: 45%;">临床建议</th>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">第一代<br>([[克唑替尼]])</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1; color: #b91c1c;"><strong>耐药</strong> (Resistant)</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">L1196M 是其主要耐药机制之一，需换药。</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">第二代<br>([[阿来替尼]] / [[塞瑞替尼]])</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1; color: #166534;"><strong>敏感</strong> (Sensitive)</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>首选方案</strong>。阿来替尼、布格替尼、恩沙替尼均有较好的抑制数据（IC50 较低）。</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">第三代<br>([[洛拉替尼]])</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1; color: #166534;"><strong>高度敏感</strong> (Highly Active)</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">作为保底方案。通常在二代药物再次耐药（如出现 G1202R）后使用。</td>
            </tr>
        </table>
    </div>

    <div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;">
        <span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span>
        
        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [1] <strong>Katayama R, et al. (2012).</strong> <em>Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers.</em> <strong>[[Science Translational Medicine]]</strong>.<br>
            <span style="color: #475569;">[机制奠基]：首次全面解析了 ALK 激酶域的耐药突变谱，确认 L1196M 为最常见的守门员突变，并阐述了其空间位阻机制。</span>
        </p>

        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [2] <strong>Gainor JF, et al. (2016).</strong> <em>Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.</em> <strong>[[Cancer Discovery]]</strong>.<br>
            <span style="color: #475569;">[临床数据]：大规模活检队列研究，显示 L1196M 在克唑替尼耐药患者中的检出率约为 7%，且通常对二代药物敏感。</span>
        </p>

        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [3] <strong>Solomon BJ, et al. (2018).</strong> <em>Lorlatinib in patients with ALK-positive non-small-cell lung cancer.</em> <strong>[[The Lancet Oncology]]</strong>.<br>
            <span style="color: #475569;">[治疗策略]：证实了洛拉替尼对包括 L1196M 在内的多种 ALK 突变具有广谱且强效的抑制作用。</span>
        </p>
    </div>

    <div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;">
        <div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;">
            L1196M · 知识图谱
        </div>
        <table style="width: 100%; border-collapse: collapse; background-color: #ffffff;">
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联基因</td>
                <td style="padding: 10px 15px; color: #334155;"><strong>[[ALK]]</strong> (NSCLC 钻石突变)</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">类似机制</td>
                <td style="padding: 10px 15px; color: #334155;">EGFR <strong>[[T790M]]</strong> • BCR-ABL T315I • ROS1 L2026M</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">更强耐药</td>
                <td style="padding: 10px 15px; color: #334155;"><strong>[[G1202R]]</strong> (溶剂前沿突变，需三代药)</td>
            </tr>
            <tr>
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">治疗药物</td>
                <td style="padding: 10px 15px; color: #334155;">[[阿来替尼]] • [[布格替尼]] • [[洛拉替尼]]</td>
            </tr>
        </table>
    </div>

</div>